In a study, Janus kinase inhibitors proved effective for patients with difficult-to-treat rheumatoid arthritis (RA).
AbbVie, Lilly Face New Delays in FDA Approval for Expanded Use of Janus Kinase Inhibitors
(Reuters)—AbbVie Inc. and ELi Lilly & Co. are facing fresh delays in the approval of their respective rheumatoid arthritis (RA) drugs for treating the chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The treatment, called Janus kinase inhibitors (jakinibs), blocks inflammation-causing enzymes known as Janus…
CDC Advisers Consider Boosters for Immune-Compromised Americans
CHICAGO (Reuters)—Advisers to the U.S. Centers for Disease Control & Prevention will consider evidence suggesting that a booster dose of COVID-19 vaccines could increase protection among people with compromised immune systems. Data presented ahead of the July 22 meeting noted that people with compromised immune systems have a reduced antibody response following the recommended primary…
Will an App to Monitor Patient Outcomes Improve RA Disease Activity?
Lee et al. examined the use of a smartphone application to monitor longitudinal electronic patient-reported outcomes on satisfaction and disease activity in patients with RA.
Learn to Share Your Voice at Advocacy 101
Applications are now open for the ACR’s Advocacy 101 program, held in conjunction with Advocates for Arthritis. Amanda Schnell, MD, describes how ACR/ARP members can learn to be successful advocates for rheumatology.
2022 Physician Fee Schedule Proposed Rule Released
In the proposed rule released July 13, the ACR is encouraged by the continued implementation of evaluation and management reimbursement adjustments to better reflect the work and expertise needed to treat complex patient populations, the extension of many telehealth flexibilities and the inclusion of the ACR’s proposed MACRA MIPS Value Pathway for rheumatology.
Executive Order Targets Prescription Drugs & Health Insurance to Promote Competition
On July 9, U.S. President Joe Biden issued an Executive Order designed to promote competition in the U.S. economy. The order includes 72 initiatives related to various aspects of the economy, including prescription drugs and health insurance.1 For prescription drugs, Americans pay more than 2.5 times as much for the same prescription drugs as patients…
Steven Echard Shares ACR Collaborative Plans at Florida Society Meeting
At the recent Florida Society of Rheumatology meeting, ACR executive vice president Steven Echard, IOM, CAE, emphasized the role of collaborations with state organizations in the ACR’s plans to modernize and expand its activities and offerings.
2022 Proposed Rule for the Quality Payment Program Released
ACR staff have highlighted critical changes for the 2022 performance year outlined in the proposed rule released July 13 by the Centers for Medicare & Medicaid Services.
Treatment Factors to Consider in Patients with JIA
Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.
- « Previous Page
- 1
- …
- 136
- 137
- 138
- 139
- 140
- …
- 814
- Next Page »